Vycor Medical Reports 31% Increase in Third-Quarter Revenue
Vycor Medical Inc. reported revenue of $513.8 thousand for the three months ended September 30, 2025, a 31.4% increase from $390.9 thousand in the same period in 2024. The Vycor Medical division generated $492.1 thousand, up 32% year over year, primarily due to growth in the US. The NovaVision division, still in development, recorded sales of $21.7 thousand, up from $18.0 thousand in 2024. Gross profit for the quarter was $451.9 thousand with a gross margin of 88%, compared to $354.1 thousand and a 90% margin in 2024, with the margin decrease attributed to validation and shipping costs of new production runs. For the nine months ended September 30, 2025, the company reported revenue of $1.45 million, a 27.5% increase from $1.13 million in 2024. Vycor Medical division revenue rose 29.1% to $1.39 million, mainly due to international market growth. NovaVision sales were $54.1 thousand compared to $55.5 thousand in 2024. The gross profit margin for the period was 84%, down from 90% in 2024, due to higher costs and international sales mix.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vycor Medical Inc. published the original content used to generate this news brief on November 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.